Long-term follow-up of a hemifacial lentigo maligna treated using 5% imiquimod.
Ramsdell
Anne M
AM
Department of Dermatology, Roswel Park Cancer Institute, Buffalo, New York 14263, USA. delles@buffalo.edu
Zeitouni
Nathalie
N
D000287:Administration, Topical; D000369:Aged, 80 and over; D000634:Aminoquinolines / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001706:Biopsy; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D018327:Hutchinson's Melanotic Freckle / Q000188:drug therapy* / Q000473:pathology; D000077271:Imiquimod; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod